Revascularization for Left Main Disease: Updated Data, Global Guideline and Beyond

Left Main and Multi-Vessel Diseases: Updated Concept and Treatment

Choosing Wisely: FFR vs. Anatomy-guided Left Main PCI -The Rationale of the FATE-MAIN Trial

Left Main and Multi-Vessel Diseases: Updated Concept and Treatment


Implications of the ISCHEMIA Trial on Patient Selection for CTO-PCI

CTO-PCI: To Treat, or Not To Treat

ASSURE-DES Trial: Optimal Antiplatelet Strategy in DES Patients During Noncardiac Surgery

Ongoing Trials from Asan Medical Center


OCTIVUS Trial: OCT- vs. IVUS-guided PCI in All-comer PCI

Late-Breaking Clinical Trials 2024

PREVENT trial: Confirmative RCT of Preventive PCI for Vulnerable Plaques

Vulnerable Plaque Treatment 2024


Long-term DOAC Management of AF and Stable CAD: Expectation on the EPIC-CAD Trial After the AFIRE Trial

All About New Data of Antithrombotics

50 Years Long Journey of Coronary Physiology: From Humble To Great

TCTAP "Master of the Masters" Award 2024


DCB Use in Your PCI Practice: Adjunctive Therapy or Standard of Care?

Evolving PCI Devices: Coronary DES, BRS, and DCB

What Are Novel and Future Antithrombotic Drugs in ACS and PCI? Are There Still Unmet Needs?

Antithrombotic Hot Issues in ACS/PCI: What Are New in 2024?


TAVR-in-TAVR: The NEXT Challenging Issue in Lifetime TAVR Management

TAVR: Key Issues in 2024

GE HealthCare
B Braun
Chong Kun Dang